Ariad Announces Updated Findings from Pivotal Pace Trial of Ponatinib to Be ... 
MarketWatch (press release)
This trial is being conducted in patients with chronic myeloid leukemia (CML) and Philadelphia-chromosome positive acute lymphoblasatic leukemia (Ph + ALL) who are resistant or intolerant to either nilotinib or dasatinib, two currently available CML ...

and more » 

New Data from Bristol-Myers Squibb Oncology Portfolio to be Presented at 2012 ... 
MarketWatch (press release)
Gleevec(R)* (imatinib mesylate) in the treatment of patients with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic-phase. Long-term follow up data (6 years) from the Phase 3 study (-034) that evaluated ...

and more » 

Schoolgirl diagnosed with cancer after she recognised symptoms while watching ... 
Daily Mail
Alex Cooper, 17, has just been told she is in remission after two years of chemotherapy to treat potentially deadly chronic myeloid leukaemia. But it could have been very different if it weren't for the schoolgirl spotting she had the same symptoms as ...
Teenager self-diagnosed leukaemia after watching Cameron Diaz film Parentdish
Teen girl credits Cameron Diaz movie for saving her life Zee News
Cameron Diaz film saved my life, says cancer survivor Metro

all 9 news articles » 

Nilotinib superior to imatinib in older patients with CML in chronic phase 
Oncology Nurse Advisor
NEW ORLEANS?Nilotinib has superior safety and efficacy over imatinib in older patients with chronic myeloid leukemia in chronic phase, according to research presented at the Oncology Nursing Society (ONS) 37 th Annual Congress. Although chronic ...

 

UK Health Body Approves Novartis's Tasigna For CML 
Fox Business
LONDON ? The UK's health-cost regulator has decided to back an expensive cancer drug from Novartis AG (NVS) for treating chronic myeloid leukemia--but not one from US-based Bristol-Myers Squibb Co. (BMY)--after the Swiss drug maker offered to cut the ...
UK NICE issues final guidance for Tasigna, Glivec, Sprycel, Victrelis and Incivo The Pharma Letter

all 2 news articles » 

Pfizer To Present New Data In Advanced Kidney, Lung And Hematologic Cancers At ... 
FiercePharma
Late last year, 24-month follow-up data from the Bosutinib Efficacy and safety in chronic myeloid Leukemia (BELA) Phase 3 study was presented at the 54th annual meeting of the American Society of Hematology (ASH). -- Efficacy and safety of bosutinib ...

and more » 

Commentary: Join me in the fight against blood cancers 
Daily Pilot
These advances include Gleevec, used for chronic myelogenous leukemia, Velcade for multiple myeloma, and Rituxan used primarily for non-Hodgkin's lymphoma. It is an honor and a privilege to be there for people affected by cancer.

and more » 

ARIAD Reports First Quarter 2012 Financial Results and Development Progress 
MarketWatch (press release)
Updated clinical data from the pivotal PACE trial of ponatinib, our investigational pan-BCR-ABL inhibitor in patients with chronic myeloid leukemia (CML) and Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ALL), will be presented at ...

and more » 

Teen spots her cancer symptoms in movie 
Ninemsn
Concerned by what she saw she consulted a doctor who diagnosed her with chronic myeloid leukaemia. Fortunately the cancer was detected early and an aggressive course of chemotherapy managed to beat the disease and she is now in remission.

and more » 

Gleevec - $1.51 billion 
FiercePharma
Gleevec is one of the revolutionary drugs that has transformed some blood cancers into chronic illnesses rather than death sentences. According to one study cited in Science Life, 5-year survival rates for patients with chronic myelogenous leukemia was ...